Share on linkedin

Ongoing Trials in Europe

Ongoing phase II/III academic trials in Europe

Trial AcronymTrial objectivePrincipal investigator Participating countries
ESOPECPerioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the EsophagusJ Hoeppner (GR) GR
ENDEAVOREndoscopic brush cytology and single cell clonal dynamics of early esophageal adenocarcinoma for detecting cost effective surveillance strategies and prediction of cancer recurrenceProf. Dr. Sheila KrishnadathBE, IT, IE, SE, DE, FR, NL, DK
NeoAEGISTo compare neoadjuvant chemotherapy (MAGIC regimen) to neoadjuvant chemoradiotherapy (CROSS regimen) in junctional adenocarcinomaJV Reynolds (IRL)IRL, UK, FR, DEN
ESOSTRATE – PRODIGE 32To compare systematic surgery versus surveillance in complete morphological responders to chemoradiotherapy in oesophageal cancerL Bedenne – C Mariette (FR)FR
ROMIOTo compare hybrid vs totally mini-invasive vs open oesophagectomy in oesophageal cancerJ Blazeby (UK)UK
Pre-SANOCorrelation between clinical Complete Response and pathological Complete Response after neoadjuvant chemoradiotherapyJJB Van Lanschot (NL)NL
PROTECTTo compare 2 neoadjuvant chemoradiotherapy regimen in oesophageal cancer: Carboplatin-Paclitaxel +radiotherapy (CROSS regimen) vs. Folfox + radiotherapyA Adenis – C Mariette (FR)FR
FREGATMulticenter, Nationwide Prospective data collection of clinical, tumoural, biological, quality of life and human and social sciences data for oesphageal and gastric cancer patientsC Mariette (FR)FR
ROBOTRobot vs open transthoracic oesophagectomy for oesophageal cancerR. van Hillegersberg (NL)NL
CONCORDE – PRODIGE 26Radiotherapy dose escalation in definitive chemoradiotherapy for oesophageal cancer 50.4 Gy vs. 64 GyG Crehange (FR)FR
ART decoRadiotherapy dose escalation in definitive chemoradiotherapy for oesophageal cancer 50.4 Gy vs. 61.6 GyM.C.C.M. Hulshof (NL)NL
NEORES IIRandomized clinical trial comparing the timing of resective surgery after neoadjuvant chemoradiotherapy in cancer of the esophagus or gastric cardia

ESDE / ISDE
Congress 2027